Six drugs excluding 17beta-estradiol (E2) were validated concerning treatment for lung cancer in some studies (33, 39–42) yet 17beta-estradiol (E2) was also a targeted drug predicted by lncRNA HOXA11-AS, further indicating that 17beta-estradiol (E2) could be a candidate drug in the process of LUAD metastasis. Here, HOXA11 is linked to lung cancer.